Comment diagnostiquer une hyperuricémie ?

Un test sanguin mesure le taux d'acide urique pour diagnostiquer l'hyperuricémie.

Quels tests pour la goutte ?

L'analyse du liquide synovial et des tests sanguins pour l'acide urique sont utilisés.

Quels symptômes indiquent une crise de goutte ?

Douleur intense, rougeur et gonflement d'une articulation, souvent le gros orteil.

Comment évaluer une maladie liée aux purines ?

Des tests génétiques et des analyses biochimiques peuvent être nécessaires.

Quel rôle des purines dans le diagnostic ?

Les niveaux de purines peuvent indiquer des troubles métaboliques ou des maladies rénales.

Quels sont les symptômes de l'hyperuricémie ?

Souvent asymptomatique, mais peut causer des douleurs articulaires et des calculs rénaux.

Quels signes de goutte aiguë ?

Douleur intense, rougeur, chaleur et gonflement d'une articulation, souvent nocturne.

Comment se manifeste une crise de goutte ?

Une douleur soudaine et sévère dans une articulation, souvent accompagnée d'inflammation.

Quels symptômes des troubles des purines ?

Fatigue, douleurs articulaires, et parfois des problèmes rénaux ou hépatiques.

Quels symptômes d'une maladie de Wilson ?

Accumulation de cuivre, troubles neurologiques, et symptômes hépatiques.

Comment prévenir l'hyperuricémie ?

Adopter un régime pauvre en purines et éviter l'alcool et les boissons sucrées.

Quelles habitudes pour éviter la goutte ?

Maintenir un poids santé, rester hydraté et limiter les aliments riches en purines.

Comment réduire le risque de calculs rénaux ?

Boire beaucoup d'eau et éviter les aliments riches en oxalates et purines.

Quels conseils diététiques pour les purines ?

Limiter les viandes rouges, les fruits de mer et les boissons alcoolisées.

Comment surveiller les niveaux d'acide urique ?

Des tests sanguins réguliers pour surveiller les niveaux d'acide urique et ajuster le régime.

Comment traiter l'hyperuricémie ?

Des médicaments comme les inhibiteurs de la xanthine oxydase et des changements alimentaires.

Quel traitement pour la goutte ?

Anti-inflammatoires non stéroïdiens (AINS) et colchicine pour soulager la douleur.

Comment prévenir les crises de goutte ?

Éviter les aliments riches en purines et maintenir une hydratation adéquate.

Quels médicaments pour les troubles des purines ?

Des médicaments spécifiques selon le trouble, comme les uricosuriques pour l'hyperuricémie.

Comment gérer les calculs rénaux liés aux purines ?

Hydratation, modifications alimentaires et parfois intervention chirurgicale.

Quelles complications de la goutte ?

Arthrite chronique, dépôts de tophus et risque accru de maladies cardiovasculaires.

Quels risques liés à l'hyperuricémie ?

Peut entraîner des calculs rénaux, des maladies rénales et des problèmes cardiovasculaires.

Comment l'hyperuricémie affecte-t-elle les reins ?

Peut provoquer une néphropathie urique, entraînant des lésions rénales.

Quelles complications des troubles des purines ?

Peuvent inclure des problèmes hépatiques, neurologiques et des troubles métaboliques.

Quels effets à long terme de la goutte ?

Peut entraîner des dommages articulaires permanents et des complications systémiques.

Quels facteurs de risque pour l'hyperuricémie ?

Obésité, consommation excessive d'alcool, régime riche en purines et antécédents familiaux.

Qui est à risque de goutte ?

Les hommes, les personnes obèses et celles ayant des antécédents familiaux de goutte.

Quels médicaments augmentent le risque d'hyperuricémie ?

Diurétiques, aspirine à faible dose et certains médicaments immunosuppresseurs.

Quel rôle de l'alimentation dans les purines ?

Une alimentation riche en viandes rouges, fruits de mer et boissons sucrées augmente le risque.

Comment l'âge influence-t-il l'hyperuricémie ?

Le risque d'hyperuricémie augmente avec l'âge, surtout chez les hommes après 40 ans.

Purines - Informations médicales vérifiées

Cardiac resynchronization therapy defibrillator: a

08 2022

DOI: 10.2217/fca-2021-0055 PMID: 35735185

The COVID-19 pandemic has seriously revolutionized the management of patients who need an implanted cardiac implantable electronic device. We report, for the first time, a successful cardiac resynchro...

Aged, 80 and over COVID-19 Cardiac Resynchronization Therapy Defibrillators, Implantable Electric Countershock +5 autres

Cardiac resynchronization therapy response in cardiac sarcoidosis.

09 2022

DOI: 10.1111/jce.15631 PMID: 35870183

Cardiac sarcoidosis (CS) is a nonischemic cardiomyopathy (NICM) characterized by infiltration of noncaseating granulomas involving the heart with highly variable clinical manifestations that can inclu... To determine if CRT improved cardiac remodeling in patients with CS.... We retrospectively reviewed all patients with a clinical or histological diagnosis of CS who underwent CRT implantation at the Mayo Clinic enterprise from 2000 to 2021. Baseline characteristics, imagi... Our cohort was comprised of 55 patients with 61.8% male and a mean age of 58.7 ± 10.9 years. Eighteen (32.7%) patients had definite CS, 21 (38.2%) had probable CS, while 16 (29.1%) had presumed CS, an... Our findings suggest variable response to CRT in patients with CS with no overall improvement in ventricular function within 6 months and a substantial proportion of patients progressing to advanced h...

Aged Cardiac Resynchronization Therapy Cardiomyopathies Defibrillators, Implantable Female +8 autres

Significance of effective cardiac resynchronization therapy pacing for clinical responses: An analysis based on the effective cardiac resynchronization therapy algorithm.

09 2023

DOI: 10.1016/j.hrthm.2023.06.005 PMID: 37307884

High percent ventricular pacing maximizes cardiac resynchronization therapy (CRT) response. An effective CRT algorithm classifies each left ventricular (LV) pace as effective or ineffective on the bas... We aimed to clarify the association between %e-CRT and clinical outcomes.... Of the 136 consecutive CRT patients, 49 using the adaptive and effective CRT algorithm with percent ventricular pacing > 90% were evaluated. The primary and secondary outcomes were heart failure (HF) ... We divided the patients into the effective group (n = 25) and the less effective group (n = 24) by the median value of %e-CRT (97.4% [93.7%-98.3%]). During the median follow-up period of 507 days (int... High %e-CRT is associated with high CRT responder prevalence and low HF hospitalization risk....

Humans Cardiac Resynchronization Therapy Treatment Outcome Cardiac Resynchronization Therapy Devices Heart Failure +1 autres

Women are underrepresented in cardiac resynchronization therapy trials.

12 2022

DOI: 10.1111/jce.15715 PMID: 36259727

Current guidelines for cardiac resynchronization therapy (CRT) device implant are the same across both sexes however women have been traditionally underrepresented in randomized controlled trials (RCT... RCTs evaluating the benefit of CRT in HF patients referenced in the 2012 EHRA/HRS expert consensus statement on CRT in HF were included. Studies were evaluated for gender representation, baseline vari... A total of 10 CRT trials including 8107 patients were studied. Of the total patient population in these RCTs, only 23% were women. Analysis of outcomes based on sex was reported only in 5 out of 10 tr... Women are underrepresented in CRT trials; however, they have been shown to derive a greater benefit from CRT compared to men. Appropriate measures should be taken in future studies to enhance the part...

Male Female Humans Cardiac Resynchronization Therapy Treatment Outcome +4 autres

Conduction System Pacing for Cardiac Resynchronization Therapy.

06 2022

DOI: 10.1016/j.ccep.2021.12.005 PMID: 35715087

Although conventional biventricular pacing has been shown to benefit patients with heart failure and conduction system disease, there are limitations to its therapeutic success, resulting in widely va...

Bundle of His Bundle-Branch Block Cardiac Resynchronization Therapy Electrocardiography Heart Conduction System +3 autres

Status and Update on Cardiac Resynchronization Therapy Trials.

06 2022

DOI: 10.1016/j.ccep.2021.12.007 PMID: 35715089

After decades of clinical use, cardiac resynchronization therapy (CRT) can be considered an established therapy. However, there are multiple open questions to be addressed that shall further improve t...

Cardiac Resynchronization Therapy Defibrillators, Implantable Heart Failure Heart Rate Heart Ventricles +2 autres

Long-term outcomes in nonprogressors to cardiac resynchronization therapy.

02 2023

DOI: 10.1016/j.hrthm.2022.10.029 PMID: 36356725

Among patients with heart failure undergoing cardiac resynchronization therapy (CRT), patients with a minimal change in left ventricular ejection fraction (LVEF) have recently been defined as "nonprog... We sought to evaluate outcomes in patients undergoing CRT on the basis of echocardiographically determined response status.... We reviewed the medical charts of patients with an LVEF of ≤35% and a QRS duration of ≥120 ms undergoing CRT at the Cleveland Clinic, Johns Hopkins Hospital, and Johns Hopkins Bayview Medical Center b... A total of 1058 patients were included and had a mean follow-up 8.7 ± 5.4 years, over which time there were 606 end points (37 LVAD implants, 32 heart transplants, and 537 deaths). Survival free of LV... Nonprogressors to CRT have superior medium-term outcomes but similar long-term outcomes to progressors and inferior outcomes to responders and super-responders....

Humans Cardiac Resynchronization Therapy Heart Failure Stroke Volume Treatment Outcome +1 autres

Multisite Left Ventricular Pacing in Cardiac Resynchronization Therapy.

06 2022

DOI: 10.1016/j.ccep.2021.12.003 PMID: 35715083

Cardiac resynchronization therapy (CRT) is an established treatment of patients with heart failure with reduced ejection fraction and prolonged ventricular depolarization on surface electrocardiogram....

Cardiac Resynchronization Therapy Heart Failure Heart Ventricles Humans Treatment Outcome +1 autres

Cost-effectiveness analysis of leadless cardiac resynchronization therapy.

Dec 2023

DOI: 10.1111/jce.16102 PMID: 37814470

The Wireless Stimulation Endocardially for CRT (WiSE-CRT) system is a novel technology used to treat patients with dyssynchronous heart failure (HF) by providing leadless cardiac resynchronization the... A cost-effectiveness evaluation of the WiSE-CRT System was performed using a cohort-based economic model adopting a "proportion in state" structure. In addition to the primary analysis, scenario analy... The primary analysis demonstrated that treatment with the WiSE-CRT system is likely to be cost-effective over a lifetime horizon at a QALY reimbursement threshold of £20 000, with a net monetary benef... Within the model limitations, these findings support the use of WiSE-CRT in indicated patients from an economic standpoint. However, improving battery technology should be prioritized to maximize cost...

Humans Cardiac Resynchronization Therapy Cost-Effectiveness Analysis Heart Failure Treatment Outcome

Feasibility of physiological pacing rate in cardiac resynchronization therapy.

08 2023

DOI: 10.1002/ehf2.14429 PMID: 37306670

Although cardiac resynchronization therapy (CRT) improves functional capacity in heart failure patients, a blunted heart rate (HR) response remains after treatment. So we aimed to evaluate the feasibi... A cohort of 30 clinical mildly symptomatic CRT patients underwent the six-minute walk test (6MWT). During the 6MWT, HR, blood pressure, and maximum walking distance were assessed. The measurements wer... During the 6MWT, CRT PPR led to an increase in walking distance of 40.5 m (9.2%; P < 0.0001) when compared with baseline trial. Additionally, CRT PPR increased the maximum walking distance compared wi... In mildly symptomatic CRT patients PPR is feasible, leading to improvements in functional capacity. In this regard, the efficacy of PPR must be confirmed by controlled randomized trials....

Humans Cardiac Resynchronization Therapy Feasibility Studies Treatment Outcome Heart Failure +1 autres

Purines : Questions médicales fréquentes

Termes MeSH sélectionnés :

Questions fréquentes et termes MeSH associés

Diagnostic 5

Symptômes 5

Prévention 5

Traitements 5

Complications 5

Facteurs de risque 5

Contenu validé par Dr Olivier Menir

Sous-catégories

Adénine

Allopurinol

Mercaptopurine

Purinones

Roscovitine

Citrate de sildénafil

Tioguanine

Amino-2 purine

Cytokinine

Famciclovir

Ténofovir

Hypoxanthines

Xanthines

Kinétine

Zéatine

Guanine

Hypoxanthine

Caféine

Théobromine

Théophylline

Acide urique

Xanthine

Aciclovir

8-Azaguanine

Pentoxifylline

Diphylline

Xanthine(isobutyl-3 methyl-1)

Nicotinate de xanthinol

Ganciclovir

Valaciclovir

Valganciclovir

Auteurs principaux

Sources (10000 au total)